Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Centessa Pharmaceuticals plc - American Depositary Shares (NQ:CNTA)

25.30 -0.42 (-1.63%)
Streaming Delayed Price Updated: 2:34 PM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Centessa Pharmaceuticals plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, appointed Chief Executive Officer and member of the Board of Directors 
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗
Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗
One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next. 
Via The Motley Fool
News headline image
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗
A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗
This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗
A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks. 
Via The Motley Fool
News headline image
Why Centessa Pharmaceuticals Stock Crushed the Market Today ↗
Investors were optimistic about the company potentially reaping $250 million in gross proceeds from an equity offering. 
Via The Motley Fool
News headline image
Neural Gold Rush: Is Brain Data the Most Precious Commodity of the Century?
As the digital age continues its relentless march, a new contender has emerged for the title of the world's most valuable commodity: neural data. Far surpassing traditional resources like oil or even... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
These stocks that are showing activity before the opening bell on Wednesday. ↗
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
This Domino's Pizza Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
CENTESSA PHARMACEUTICALS-ADR (NASDAQ:CNTA) Shows Strong Technical Setup for Potential Breakout ↗
CNTA stock shows strong technical momentum and a high-quality consolidation pattern, signaling a potential breakout for traders. 
Via Chartmill
News headline image
3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores ↗
A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores. 
Via Benzinga
News headline image
Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. ↗
All four companies are testing out orexin agonists to improve the symptoms of narcolpesy. 
Via Investor's Business Daily
News headline image
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
AeroVironment Posts Downbeat Results, Joins Box, CrowdStrike And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.